-
-
-
-
-
-
-
Q32 Bio (QTTB) Misses Q4 EPS by 116c
-
-
-
-
-
-
-
Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis
-
-
-
-
-
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

